Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.

Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page
- CheckyesterdayChange DetectedLocations were updated with many new sites across the US and internationally, and several existing sites were removed.SummaryDifference3%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRemoved related topics entries for Melanoma and MedlinePlus Genetics from the Related Topics section.SummaryDifference0.1%

- Check23 days agoChange DetectedRelated topics Melanoma and MedlinePlus Genetics were added to the page, and the revision version was updated from v3.3.1 to v3.3.2.SummaryDifference0.1%

- Check30 days agoChange DetectedAdded a note that publications are automatically filled from PubMed. Updated the page revision to v3.3.1 and removed older PubMed-related wording (v3.2.0).SummaryDifference0.1%

- Check37 days agoChange DetectedRemoval of the government funding status banner; the page's study content and navigation remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check51 days agoChange Detected- Added a new citation under Publications From PubMed: Nivolumab for Resected Stage III or IV Melanoma at 9 Years, N Engl J Med, 2025 Oct 18. - No other page content was altered.SummaryDifference0.2%

Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.